Developing Systemic Therapy for Esophagogastric Cancer

Eleven votes were cast against the favorability of using anti–PD-1 inhibitors in patients with ESCC and a PD-L1 expression of less than 1.

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.